Mersana Therapeutics Inc (Mersana) is a pharmaceutical company. It develops antibody-drug conjugates (ADC) for the treatment of cancer. The company’s pipeline products XMT-1660, XMT-2056, XMT-2068, and XMT-2175 an ADC that targets sodium-dependent phosphate transport protein NaPi2b utilizing the Dolaflexin platform. Mersana utilizes various technologies including DolaLock Technology, Dolaflexin, Dolasynthen, and Immunosynthen in developing ADCs. Its products also include ASN004 which is in the dose escalation stage. The company develops immunoconjugates to deliver payloads of anti-tumor agents directly to cancerous cells. Its products are used to treat multiple cancer indications including gastric cancer and metastatic breast cancer. Mersana is headquartered in Cambridge, Massachusetts, the US.
Mersana Therapeutics Inc premium industry data and analytics
Products and Services
Products |
---|
Pipeline |
XMT-1660 |
XMT-2056 |
XYZ |
XYZ |
XYZ |
Competitor Comparison
Key Parameters | Mersana Therapeutics Inc | Endonovo Therapeutics Inc | Aprea Therapeutics Inc | Cavion Inc | Odonate Inc |
---|---|---|---|---|---|
Headquarters | United States of America | United States of America | United States of America | United States of America | United States of America |
City | Cambridge | Woodland Hills | Doylestown | Charlottesville | New York |
State/Province | Massachusetts | California | Pennsylvania | Virginia | New York |
No. of Employees | 123 | - | 9 | - | 137 |
Entity Type | Public | Public | Public | Private | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
Name | Position | Board | Since | Age |
---|---|---|---|---|
David Mott | Chairman | Executive Board | 2012 | 57 |
Martin Huber, M.D. | Chief Executive Officer; Director; President | Executive Board | 2023 | - |
Brian DeSchuytner | Chief Operating Officer; Chief Financial Officer; Senior Vice President | Senior Management | 2023 | - |
Ashish Mandelia | Vice President; Chief Accounting Officer | Senior Management | 2023 | - |
Alejandra Carvajal | Chief Legal Officer; Senior Vice President | Senior Management | 2021 | 49 |
Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Access more premium companies when you subscribe to Explorer
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward